<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00538</drugbank-id>
  <drugbank-id>APRD00993</drugbank-id>
  <name>Gadoversetamide</name>
  <description>Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.</description>
  <cas-number>131069-91-5</cas-number>
  <unii>RLM74T3Z9D</unii>
  <average-mass>661.76</average-mass>
  <monoisotopic-mass>662.154667866</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. MR images are based primarily on proton density and proton relaxation dynamics. MR instruments are sensitive to two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). Paramagnetic agents contain one or more unpaired electrons that enhance the T1 and T2 relaxation rates of protons in their molecular environment. In MRI, visualization of normal and pathological brain, spinal and hepatic tissue depends in part on variations in the radio frequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoversetamide shortens the T1 and T2 relaxation times in tissues where it accumulates. At the recommended dose, the effect is primarily on T1 relaxation time, and produces an increase in signal intensity (brightness). Gadoversetamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in CNS lesions that may have a normal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoversetamide in lesions such as neoplasms, abscesses, and subacute infarcts.</mechanism-of-action>
  <toxicity/>
  <metabolism>None detected</metabolism>
  <absorption/>
  <half-life>Distribution 13.3 &amp;plusmn; 6.8 (mean) minutes, elimination 103.6 &amp;plusmn; 19.5 (mean) minutes.</half-life>
  <protein-binding/>
  <route-of-elimination>The mean cumulative urinary excretion of gadoversetamide at 72 hours was approximately 93.5% for renal impaired patients and 95.8% for subjects with normal renal function</route-of-elimination>
  <volume-of-distribution>* 162 Â± 25 mL/kg [normal subjects]</volume-of-distribution>
  <clearance>* 72 +/- 16.3 mL/hr/kg [healthy]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.</description>
    <direct-parent>Alpha amino acid amides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>Alpha amino acids</alternative-parent>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid salts</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Dialkyl ethers</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic salts</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <alternative-parent>Tricarboxylic acids and derivatives</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Alpha-amino acid</substituent>
    <substituent>Alpha-amino acid amide</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid salt</substituent>
    <substituent>Dialkyl ether</substituent>
    <substituent>Ether</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
    <substituent>Tricarboxylic acid or derivatives</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="german" coder="inn">Gadoversetamid</synonym>
    <synonym language="spanish" coder="inn">Gadoversetamida</synonym>
    <synonym language="english" coder="inn/ban/usan">Gadoversetamide</synonym>
    <synonym language="latin" coder="inn">Gadoversetamidum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/001</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/002</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/003</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/004</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/005</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/006</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/007</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/008</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/009</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/010</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/011</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/012</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/013</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Mallinckrodt Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000745</ema-product-code>
      <ema-ma-number>EU/1/07/398/014</ema-ma-number>
      <started-marketing-on>2007-07-23</started-marketing-on>
      <ended-marketing-on>2017-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 micromol/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Liebel-Flarsheim Company LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0019-1177</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-22</started-marketing-on>
      <ended-marketing-on>2018-09-15</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.5 mmol/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020976</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Liebel Flarsheim Company Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242986</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-20</started-marketing-on>
      <ended-marketing-on>2018-03-23</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>330.9 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Liebel Flarsheim Company Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393158</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>330.9 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Liebel Flarsheim Company Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393166</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>330.9 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Liebel Flarsheim Company Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393174</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>330.9 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Optimark</name>
      <labeller>Liebel Flarsheim Company Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02393182</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>330.9 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
    <mixture>
      <name>Optimark</name>
      <ingredients>Gadoversetamide</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Mallinckrodt Inc.</name>
      <url>http://www.mallinckrodt.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Mallinckrodt inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Optimark 330.9 mg/ml vial</description>
      <cost currency="USD">4.49</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Contrast Media</category>
      <mesh-id>D003287</mesh-id>
    </category>
    <category>
      <category>Diagnostic Uses of Chemicals</category>
      <mesh-id>D064907</mesh-id>
    </category>
    <category>
      <category>Gadolinium-based Contrast Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Magnetic Resonance Contrast Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Magnetic Resonance Imaging Contrast Media</category>
      <mesh-id/>
    </category>
    <category>
      <category>Other Diagnostics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Paramagnetic Contrast Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Paramagnetic Contrast Media</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>0.5 mmol/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>500 micromol/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>330.9 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V08CA06">
      <level code="V08CA">Paramagnetic contrast media</level>
      <level code="V08C">MAGNETIC RESONANCE IMAGING CONTRAST MEDIA</level>
      <level code="V08">CONTRAST MEDIA</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>36:89.00*</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00538.pdf?1265922800</fda-label>
  <patents>
    <patent>
      <number>5130120</number>
      <country>United States</country>
      <approved>1992-07-14</approved>
      <expires>2009-07-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.36</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.98e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>gadolinium(3+) ion 2-[bis({2-[(carboxylatomethyl)({[(2-methoxyethyl)carbamoyl]methyl})amino]ethyl})amino]acetate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>gadolinium(3+) ion 2-[bis({2-[(carboxylatomethyl)({[(2-methoxyethyl)carbamoyl]methyl})amino]ethyl})amino]acetate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>661.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>662.154667866</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Gd+3].COCCNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NCCOC)CC([O-])=O)CC([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H34GdN5O10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>HBEAOBRDTOXWRZ-UHFFFAOYSA-K</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>206.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>154.49</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>49.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>2.32</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12039</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31644</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>444013</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46504481</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01646</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>392041</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164743703</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Gadoversetamide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200457</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>